Baird analyst Joe Vruwink lowered the firm’s price target on Certara to $18 from $19 and keeps a Neutral rating on the shares. The firm said 2Q24 came in below expectations given services performance at large accounts amidst what continues to be choppy demand environment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara price target lowered to $20 from $23 at KeyBanc
- Certara Enhances Market Position with Chemaxon Acquisition
- Certara reaffirms FY24 adjusted EPS view 41c-46c, cosensus 43c
- Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
- Certara signs a definitive agreement to acquire Chemaxon